Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
暂无分享,去创建一个
R. Greil | G. Gamerith | D. Neureiter | T. Melchardt | T. Fuereder | G. Pall | Marie-Bernadette Aretin | L. Weiss | T. Magnes | Dominik Kiem | S. Wagner | C. Wagner | Stefan Nemec
[1] Hideaki Takahashi,et al. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan , 2022, AntiCancer Research.
[2] T. Nakano,et al. Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study , 2022, AntiCancer Research.
[3] J. Schoenfeld,et al. Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges , 2021, Frontiers in Oncology.
[4] Y. Hu,et al. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC , 2020, Scientific Reports.
[5] T. Mitsudomi,et al. Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making? , 2020, Journal of thoracic disease.
[6] Hung-Ming Wang,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.
[7] K. Grossmann,et al. Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma , 2019, Annals of Oncology.
[8] C. Escriu,et al. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response , 2019, Lung cancer.
[9] C. von Buchwald,et al. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma , 2019, British Journal of Cancer.
[10] S. M. Toor,et al. Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.
[11] L. Pleyer,et al. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group. , 2018, European Journal of Cancer.
[12] Wentao Yang,et al. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer , 2018, BMC Cancer.
[13] T. Peng,et al. Indirect comparison between pembrolizumab and nivolumab for the treatment of non‐small cell lung cancer: A meta‐analysis of randomized clinical trials , 2017, International immunopharmacology.
[14] M. Tsyganov,et al. Natural and chemotherapy-induced clonal evolution of tumors , 2017, Biochemistry (Moscow).
[15] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[16] A. Berghold,et al. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. , 2013, European journal of cancer.
[17] M. Plummer,et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.
[18] J. Salk. Clonal evolution in cancer , 2010 .
[19] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[20] T. Gorlia,et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.
[21] A. Markoe,et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.
[22] A. Schueler,et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[24] S. Taylor. Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.
[25] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.